Baseimmune, a discovery stage startup in London UK harnessing its state-of-the-art AI platform to generate vaccines against highly complex and rapidly mutating pathogens. Founded by the developers behind a number of computationally designed clinical stage vaccines at the Jenner Institute University of Oxford. After raising a $11.5M Series A co-led by MSD GHI and IQ Capital, Baseimmune is focused on the pre-clinical develop of its pipeline and looking to partner on the design and development of antigens for novel indications